Biomerica (BMRA) Releases Earnings Results, Misses Expectations By $0.02 EPS

Biomerica (NASDAQ:BMRA) announced its earnings results on Monday. The company reported ($0.07) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.02), Fidelity Earnings reports. The company had revenue of $1.26 million during the quarter, compared to analysts’ expectations of $1.58 million. Biomerica had a negative net margin of 36.36% and a negative return on equity of 45.72%.

BMRA traded down $0.10 on Wednesday, reaching $2.46. The company had a trading volume of 18,687 shares, compared to its average volume of 68,706. The company has a market capitalization of $23.92 million, a P/E ratio of -14.47 and a beta of 1.35. Biomerica has a 52-week low of $1.60 and a 52-week high of $4.33.

TRADEMARK VIOLATION WARNING: This piece of content was first published by The Lincolnian Online and is owned by of The Lincolnian Online. If you are viewing this piece of content on another site, it was stolen and reposted in violation of US and international copyright law. The original version of this piece of content can be viewed at https://www.thelincolnianonline.com/2019/04/17/biomerica-bmra-releases-earnings-results-misses-expectations-by-0-02-eps.html.

Biomerica Company Profile

Biomerica, Inc, together with its subsidiaries, develops, manufactures, and markets medical diagnostic products for the early detection and monitoring of chronic diseases and medical conditions. The company's diagnostic test kits are used to analyze blood, urine, or fecal samples from patients in the diagnosis of various diseases and other medical complications; or to measure the level of specific hormones, antibodies, antigens, or other substances, which exist in the human body in extremely small concentrations.

Recommended Story: What is total return in investing?

Earnings History for Biomerica (NASDAQ:BMRA)

Receive News & Ratings for Biomerica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biomerica and related companies with MarketBeat.com's FREE daily email newsletter.